Skip to main content

Robin Sherrington's Form 4 filing

Xenon Pharmaceuticals Inc.XENE · filed Mar 8, 2024

Accession no.
0000950170-24-028795
Filed
Mar 8, 2024
Trade date
Mar 7, 2024
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $330.3K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Robin SherringtonCIK 0001619962Officer (EVP, Strategy & Innovation)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 7, 2024Common SharesMOption exerciseAcquired+1,234$9.85F1+$12,154.99,632Direct
Mar 7, 2024Common SharesFTax withholdingDisposed−215$45.96F2−$9,881.49,417Direct
Mar 7, 2024Common SharesMOption exerciseAcquired+7,407$9.85F1+$72,958.9516,824Direct
Mar 7, 2024Common SharesFTax withholdingDisposed−1,289$45.96F2−$59,242.4415,535Direct
Mar 7, 2024Common SharesSSaleDisposed−1,019$46.15F3−$47,026.8514,516Direct
Mar 7, 2024Common SharesSSaleDisposed−6,118$46.30F4−$283,263.48,398Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 7, 2024Common SharesMOption exerciseDisposed−1,234$0.00$00Direct
Mar 7, 2024Common SharesMOption exerciseDisposed−7,407$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Referenced by the price of 2 transactions in Table I.

F2

Represents the closing price of the Company's common shares on March 6, 2024 for purposes of net settlement calculations.

Referenced by the price of 2 transactions in Table I.

F3

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.15 to $46.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

F4

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $46.25 to $46.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)